Table 1

Group and paired data for serum bile acid composition

Percentage of total serum bile acids
Patient group CA DCA CDCA UDCA LCA
Control subjects (n=16)33 (6.3)13 (1.5)1-150 49 (5.9)1-152 5.5 (1.2)0.4 (0.1)
Acromegalic patients
 Untreated with OT (n=16)44 (5.4)18 (2.7)1-151 33 (4.2)5.2 (1.2)0.6 (0.2)
 Treated with LTOT (n=16)40 (3.0)26 (2.3)31 (3.1)3.1 (1.0)0.4 (0.1)
Patients with simple constipation (n=16)35 (3.6)27 (2.3)33 (2.4)4.9 (1.0)0.4 (0.1)
Acromegalic patients—paired study (n=9)
 Before OT55 (6.6)1-153 15 (3.3)1-154 27 (5.2)3.2 (1.1)0.43 (0.1)
 During OT43 (4.1)29 (2.7)26 (3.3)3.1 (1.0)0.46 (0.2)
  • Results expressed as mean (SEM). Unless otherwise indicated, the differences between the means were not statistically significant.

  • 1-150 p<0.001 versus acromegalic patients on long term octreotide and patients with simple constipation.

  • 1-151 p<0.05 versus acromegalic patients on long term octreotide and patients with simple constipation.

  • 1-152 p<0.05 versus acromegalic patients untreated with octreotide, acromegalic patients on long term octreotide, and patients with simple constipation.

  • 1-153 p<0.05 versus acromegalic patients during octreotide treatment.

  • 1-154 p<0.001 versus acromegalic patients during octreotide treatment.

  • OT, octreotide; LTOT, long term octreotide; CA, cholic acid; DCA, deoxycholic acid; CDCA, chenodeoxycholic acid; UDCA, ursodeoxycholic acid; LCA, lithocholic acid.